Faculty

Needs Statement

This educational content will offer perspectives and real-world experience in providing buprenorphine medication for opioid use disorder in the primary care setting. View this video first.

Target Audience

The target audience includes primary care physicians, physician assistants, and nurse practitioners.

Objectives

Upon completion of this activity, participants will be able to:
1. Discuss overcoming barriers that primary care physicians, physician assistants, and nurse practitioners may have when prescribing buprenorphine in a primary care environment.
2. Identify potential personal and professional rewards in caring for opioid use disorder patients.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Other
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner, free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

In collaboration with Substance Use Disorder Research Area (SUPRA).